Targeted delivery of docetaxel to the metastatic lymph nodes: A comparison study between nanoliposomes and activated carbon nanoparticles

Asian Journal of Pharmaceutical Sciences

Volumn 10, Issue 1, 2015, Pages 64-72

  Ye, Tiantian ^a   Xu, Wen ^b   Shi, Tianyu ^a   Yang, Rui ^a   Yang, Xinggang ^a   Wang, Shujun ^a   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Department of R and D Shenyang Green Pharmaceutical CO LTD   (China)

Author keywords

Activated carbon nanoparticle; Docetaxel; Lymph node targeting; Metastatic lymph node; Nanoliposome

Indexed keywords

ACTIVATED CARBON; ACTIVATED CARBON NANOPARTICLE; DOCETAXEL; LIPOSOME; NANOLIPOSOME; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CENTRIFUGATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISPERSION; DRUG ADSORPTION; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG OXIDATION; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; ISOELECTRIC POINT; LIMIT OF QUANTITATION; LYMPH FLOW; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICROCIRCULATION; MOUSE; NANOFILTRATION; NONHUMAN; OXIDATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; SEDIMENTATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ZETA POTENTIAL;

EID: 84923015617     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2014.08.004     Document Type: Article

References (36)

1. O'Hagan D.T., Christy N.M., Davis S.S. Particulates and lymphatic drug delivery. Lymphatic transport of drugs 1992, 282. CRC Press. W.N. Charman (Ed.).
2. Charman W.N., Stella V.J. Lymphatic transport after parenteral drug administration. Lymphatic transport of drugs 1992, 279-315. CRC Press.
3. Yang F., Jin C., Jiang Y., et al. Liposome based delivery system in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev 2011, 37:633-642.
4. 2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. BBA-Biomembranes 2008, 1778:51-55.
5. Rabaça Roque Botelho M.F., Tavares Marques M.A., Freitas Gomes C.M., et al. Nanoradioliposomes molecularly modulated to study the lung deep lymphatic drainage. Rev Port Pneumol 2009, 15:261-293.
6. Okamoto K., Sawai K., Minato H., et al. Number and anatomical extent of lymph node metastases in gastric cancer: analysis using intra-lymph node injection of activated carbon particles (CH40). Jpn J Clin Oncol 1999, 29:74-77.
7. Ito T., Hagiwara A., Takagi T., et al. Local administration of methotrexate bound to activated carbon particles (MTX-CH) for treating cancers in mice. Anticancer Res 2002, 23:1401-1404.
8. Oussoren C., Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 2001, 50:143-156.
9. Gu B., Xie C., Zhu J., et al. Folate-PEG-CKK2-DTPA, a potential carrier for lymph-metastasized tumor targeting. Pharm Res 2010, 27:933-942.
10. Yang F., Hu J., Yang D., et al. Pilot study of targeting magnetic carbon nanotubes to lymph nodes. Nanomedicine 2009, 4:317-330.
11. Madru R., Kjellman P., Olsson F., et al. 99mTc-labeled superparamagnetic iron oxide nanoparticles for multimodality SPECT/MRI of sentinel lymph nodes. J Nucl Med 2012, 53:459-463.
12. Lian H.Y., Hu M., Liu C.H., et al. Highly biocompatible, hollow coordination polymer nanoparticles as cisplatin carriers for efficient intracellular drug delivery. Chem Commun 2012, 48:5151-5153.
13. Asin L., Ibarra M.R., Tres A., et al. Controlled cell death by magnetic hyperthermia: effects of exposure time, field amplitude, and nanoparticle concentration. Pharm Res 2012, 29:1319-1327.
14. Xie P., Xie Y.M., Song X., et al. Preparation and study of lymphatic targeted hydrophilic carbon black. West China J Pharm Sci 2006, 21:337-339. [in Chinese].
15. Eric K., Rowinsky M.D. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997, 48:353-374.
16. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1996, 8932:1267-1272.
17. Fulton B., Spencer C.M. Docetaxel, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Docetaxel Drugs 1996, 51:1075-1092.
18. Morikawa Y., Koike H., Sekine Y., et al. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by surviving down regulation. Biochem Biophys Res Commun 2012, 419:584-589.
19. Kintzel P.E., Michaud L.B., Lange M.K. Docetaxel-associated Epiphora. Pharmacotherapy 2006, 26:853-867.
20. Ian C.S., Steven D.H., Andrew W.H., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20:1456-1466.
21. Ridwelski K., Gebauer T., Fahlke J., et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001, 12:47-51.
22. Earhart R.H. Docetaxel (Taxotere): preclinical and general clinical information. Semin Oncol 1999, 26:8-13.
23. Verweij J. Docetaxel (Taxotere): a new anti-cancer drug with promising potential?. Br J Cancer 1994, 70:183.
24. Piccart M.J., Di L.A. Future perspectives of docetaxel (Taxotere) in front-line therapy. Semin Oncol 1997, 24:1027-1033.
25. Baker J., Ajani J., Scotté F., et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009, 13:49-59.
26. Wang S.J., Ye T.T., Yang B.Y., et al. 7-Ethyl-10-hydroxy camptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation. Drug Dev Ind Pharm 2013, 39:393-401.
27. Song S.S., Chen F., Qi H., et al. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel. Pharm Res 2014, 31:1032-1045.
28. Yan Z.Q., Wang F., Wen Z.Y., et al. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release 2012, 157:118-125.
29. Payne N.I., Timmins P., Ambrose C.V., et al. Proliposomes: a novel solution to an old problem. J Pharm Sci 1986, 75:325-329.
30. Katare O.P., Vyas S.P., Dixit V.K. Proliposomes of indomethacin for oral administration. J Microencapsul 1991, 8:1-7.
31. Oussoren C., Zuidema J., Crommelin D.J.A., et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1997, 1328:261-272.
32. Allen T.M., Hansen C.B., Guo L.S.S. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. BBA-Biomembranes 1993, 1150:9-16.
33. Patel H.M. Fate of liposomes in the lymphatics. Liposomes as drug carriers 1988, 51-61. Wiley, New York. G. Gregoriadis (Ed.).
34. Tümer A., Kirby C., Senior J., et al. Fate of cholesterol-rich liposomes after subcutaneous injection into rats. BBA-Gen Subj 1983, 760:119-125.
35. Casley-Smith J.R. The fine structure and functioning of tissue channels and lymphatics. Lymphology 1980, 13:177.
36. Hawley A.E., Davis S.S., Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev 1995, 17:129-148.